Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334418 | 0.98 | CES2 (0.46) | CES2CES1NAAAHSD11B1HDAC8 | |
| SCHEMBL8156241 | 0.95 | — | — | |
| SCHEMBL4712321 | 0.90 | — | — | |
| SCHEMBL2125601 | 0.86 | ABL1 (0.49) | CES2CES1NAAAABL1RIN1 | |
| SCHEMBL11994171 | 0.84 | NAAA (0.50) | CES2CES1NAAAABL1RIN1 | |
| SCHEMBL2124153 | 0.84 | NAAA (0.50) | CES2CES1NAAAABL1RIN1 | |
| SCHEMBL2124436 | 0.84 | NAAA (0.52) | CES2CES1NAAAHSD17B10ABL1 | |
| SCHEMBL2126800 | 0.82 | NAAA (0.55) | CES2CES1NAAAHSD17B10ALDH1A1 | |
| SCHEMBL2124572 | 0.82 | NAAA (0.55) | CES2CES1NAAAHSD17B10ALDH1A1 | |
| SCHEMBL26444136 | 0.82 | NAAA (0.55) | CES2CES1NAAAHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114013-A1 | LOW CALCEMIC, HIGHLY ANTIPROLIFERATIVE, ANALOGS OF CALCITRIOL | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-04-27 | — | — | US | disclosed |
| US-9481646-B2 | Low calcemic, highly antiproliferative, analogs of calcitriol | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-8716531-B2 | Method for producing norbornene derivative | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2014-05-06 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120108851-A1 | METHOD FOR PRODUCING NORBORNENE DERIVATIVE | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2444386-A1 | PROCESS FOR PREPARATION OF NORBORNENE DERIVATIVES | JX Nippon Oil & Energy Corporation (JP) | 2012-04-25 | — | — | EP | disclosed |
| EP-2027107-B1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20100137262-A1 | Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
| US-6111054-A | IMPROVEMENT IN DISPERSION AND STABILISATION OF PIGMENTS OR EXTENDER PARTICLES IN BINDER VEHICLES, PIGMENT PASTES OR PLASTICS FORMULATIONS IS ACHIEVED BY USING ADDITIVES PRODUCED BY SALT FORMATION FROM POLYAMINES WITH ORGANIC ACIDS | BYK-CHEMIE GMBH (DE) | 2000-08-29 | — | — | US | disclosed |
| US-3956316-A | PROGESTATIONAL AND SALT-RETAINING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114013-A1 | LOW CALCEMIC, HIGHLY ANTIPROLIFERATIVE, ANALOGS OF CALCITRIOL | VDR, CYP24A1, CYP27B1 | CES2 4268/4885CES1 1585/4885NAAA 4324/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | CES2 1222/4885CES1 871/4885NAAA 2389/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | CES2 665/4885CES1 566/4885NAAA 2028/4885 |
| US-20100137262-A1 | Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol | VDR, CYP24A1, CYP27B1 | CES2 4268/4885CES1 1585/4885NAAA 4324/4885 |
| US-20120108851-A1 | METHOD FOR PRODUCING NORBORNENE DERIVATIVE | UGT1A8, UGT8, ALG8 | CES2 1994/4885CES1 1690/4885NAAA 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.